Background. Functional variants of inosine triphosphatase (ITPA) were recently found to 2 protect against ribavirin (RBV)-induced hemolytic anemia. However, no definitive data are yet 3 available on the role of plasma RBV concentrations on Hb decrement. Moreover, no data have 4 been published on the possible interplay between these two factors. 5
INTRODUCTION. 1
Hepatitis C virus (HCV) is one of the major causes of liver cirrhosis and hepatocellular 2 carcinoma 1 . Sustained viral response (SVR), defined as undetectable plasma HCV RNA 24 3 weeks after the end of treatment, is achieved in less than 50% of patients with genotype-1 4 infection using the currently recommended regimen consisting of pegylated-interferon 5 (PEG/IFN) and ribavirin 2 . 6
Anemia is a major untoward effect of anti-HCV chronic therapy. Both PEG/IFN and ribavirin 7 (RBV) play a role in haemoglobin (Hb) decrease, although most of the responsibility is by far 8 attributable to the latter. Moreover, with the forthcoming introduction of the new HCV protease 9 inhibitors, telaprevir and boceprevir, the incidence of anemia is likely to increase, as shown by 10 the results of recent clinical trials 3-5 . 11
Repeatedly, individual RBV dose and pharmacokinetic (Pk) exposure have been found to be 12 consistent determinants of treatment-associated anemia, and recommendations on dose reduction 13 have been released in order to mitigate thw impact of RBV on the severity of anemia 6-10 . Some 14 other studies have not observed an association between hemoglobin decline and plasma RBV 15 concentrations, when multivariate analyses were performed [11] [12] [13] . 16 17 Among the non-modifiable individual factors also contributing to anemia development in 18 recipients of anti-HCV therapy, single nucleotide polymorphisms (SNPs) in the human DNA 19 region coding for inosine triphosphatase (ITPA) were identified recently as the most significant 20 variables influencing the risk of anemia. In these studies, by using a genome-wide association 21 approach, two functional variants of ITPA, including one coding and one intronic variant, were 22 found to be associated with treatment-induced anemia in HCV-infected patients 5, 14, 15 , as 23 defined by the magnitude of Hb reduction after 4 weeks of treatment. This genetically 1 determined vulnerability was subsequently confirmed in several ethnically heterogeneous 2 clinical cohorts. The association signal was accounted for by 2 functional variants in the ITPA 3 gene on chromosome 20: a missense variant in exon 2 (rs1127354, P32T) and a splice-altering 4 single nucleotide polymorphism in intron 2 (rs7270101). Both polymorphisms had previously 5 been well characterized and validated as functional variants in studies of patients with ITPase 6 deficiency, a benign inherited enzymopathy in which inosine triphosphate (the substrate for 7 ITPase) accumulates in red blood cells 16, 17 . 8
A recent study established that intraerythrocytic accumulation of ITP, as seen in carriers of such 9 anemia-protecting mutants, provides an alternative source of nucleoside-triphosphates that 10 eventually compensates for RBV-induced ATP reduction 18 . 11
Since it is not known whether any direct relationship exist between ITPA polymorphisms and 12 RBV pharmacokinetics, the effects of ITPA genetic variants (rs7270101 and rs1127354) and 13 RBV trough concentration on the development of ribavirin-associated anemia at week 4 were 14 retrospectively evaluated in HCV-mono-infected patients who underwent PEG-IFN/RBV 15 therapy, and had complete medical records as well as samples available for genetic and 16 pharmacokinetic analyses. As a simultaneous evaluation of ITPA SNPs and plasma RBV 17 concentrations for hemolytic anemia has not yet been published, we aimed to understand the 18 contribution of each factor and any possible interplay between them. 19 20 PATIENTS AND METHODS. Patients from whom DNA samples were available and who agreed to undergo genetic analyses 3 were genotyped at polymorphic sites rs1127354, rs7270101 and rs6051702 on chromosome 20 4 using the ABI TaqMan allelic discrimination kit by real time PCR using standard methodology. 5
All primers, probes, and PCR conditions are available on request. The possible genotypes for 6 each biallelic polymorphism are as follows: rs1127354: C/C, A/C, A/A (minor allele = A); 7 rs7270101: A/A, A/C, C/C (minor allele = C); rs6051702: A/A, A/C, C/C (minor allele = C). 8 9
Measurement of plasma ribavirin concentration 10
At week 4, a time associated with the achievement of RBV steady-state 19 , plasma samples were 11 collected ~12 h after the dose administration of RBV, just before the following administration 12 (trough value). Samples were centrifuged at 3000 rpm for 10 minutes to separate plasma and 13 then stored at -80°C until analysis. Ribavirin concentrations were measured by a previously 14 validated HPLC method 20 . Briefly, the extraction of RBV from an aliquot of 250 µL of plasma 15 was performed using 1500 µL of acetonitrile. The mixture was vortexed for 10 seconds and then 16 centrifuged at 12,000×g for 10 minutes at 4°C and the supernatant was dried at 50°C. The dry 17 extract was reconstituted with 125 μL of mobile phase then 30 μL was injected onto the column. 18
Chromatographic separation was performed by an Atlantis 3μm dC18 column (150mm×4.6mm 19 I.D, Waters, Milan, Italy), and RBV peak was detected at a wave length of 235 nm and retention 20 time of 4.3 minutes. The calibration curve ranged from 0.078 to 10 μg/mL. Accuracy and 21 precision standard errors were below 10%. 22
1
Definition of Clinical End Points 2
In common with most therapeutic studies on HCV chronic hepatitis treatment, Hb decline at 3
week 4 was taken as the clinical endpoint and patients were classified according to two clinical 4 cut-off: (a) absolute Hb value lower than 10 g/dL, and (b) Hb reduction >3 g/dL at week 4. 5 6
Statistical Analysis 7
For descriptive statistics, continuous variables were summarized as median (25th to 75th 8 percentiles). Categorical variables were described as frequency and percentage. All data were 9 assessed for normality using a Shapiro-Wilk test and categorical data were compared using a 10
Mann Whitney or Kruskal-Wallis statistical test. To investigate continuous data, a Spearman 11
Rank correlation was utilized. The association between individual ITPA SNP and the incidence 12 of significant Hb decline was tested by a basic allelic test and calculated using the χ 2 -test. 
RESULTS. 1
Sixty-seven out of 234 patients were excluded due to the lack of demographic and clinical 2 information, including RBV plasma evaluation at week 4. 3
Of the 167 patients included in the analysis, 90 patients (53.9%) were male, the median age was 4 46 years (IQR, 38-58 years) and the median body weight was 69 kg (IQR, 62-75 kg). 161 5 patients (96.4%) were Caucasian and 6 (3.6%) were African. 81 patients (48.5%) were treated 6 with PEG/IFN-a-2a (180 µg/ once a week) and 86 (51.5%) were treated with PEG/IFN-a-2b (1. The two functional ITPA SNPs, responsible for inosine triphosphatase deficiency, (rs1127354 20 and rs7270101) and the co-segregate SNP (rs6051702) were associated with the magnitude of 21 hemoglobin decrease. Patients with rs1127354CC (n=151) had a larger hemoglobin decrement (-22 2.5 g/dL, IQR -3.6 to -1.4), as compared to patients with CA/AA genotypes (-0.8 g/dL, IQR -1.1 23 to -0.4, p=3.06x10 -6 ). Similarly patients with genotype rs7270101AA (n=133) had a larger 1 hemoglobin decrement (-2.5 g/dL, IQR -3.6 to -1.4), as compared to patients with AC/CC (-1.7 2 g/dL, IQR -2.5 to -0.7, p = 0.002) and patients with rs6051702AA (n=129) had a larger 3 hemoglobin decrement (-2.7 g/dL, IQR -3.7 to -1.7) as compared to patients with AC/CC (-1.1 4 g/dL, IQR -1.9 to -0.7, p=3.4x10 -9 ). 5
Despite the strong association between the hemoglobin decrement and the polymorphism 6 rs6051702, in the following statistical analysis we have considered only the two functional 7 polymorphisms of the gene ITPA, as described by other authors 5, 21, 22 . 8
As showed in Figure 1 , the carrier of at least one variant allele in the functional ITPA SNPs was 9 associated with a smaller decrement of Hb (p=4.09x10 -8 ). In particular, patients with at least a 10 variant allele in the functional ITPA SNPs (n=49) had a lower hemoglobin decrement (-1.1 g/dL, 11 IQR -2.3 to -0.6), as compared to patients (n=118) without a variant allele (-2.75 g/dL, IQR -3.7 12 to -1.7). No differences in Hb baseline between the wild type genotype patients and the carriers 13 of a least one mutation for ITPA gene were observed (p=0.843 To define the clinical relevance of genetic variants, trough concentration of RBV and other 4 variables, we analyzed the proportion of patients with clinically significant anemia, which was 5 defined as a decline of Hb more than 3 g/dL or an absolute Hb value lower than 10 g/dL. As 6 summarized in Table 1 , differences could be detected for baseline Hb, RBV trough 7 concentrations and possession of variant alleles in the two SNPs. 8 By using ROC curve analysis, a cut-off of plasma RBV concentration of 2.3 μg/mL was found to 9 be associated with anemia (Area-Under-ROC=0.630, sensitivity=50.0% and specificity=69.5%, 10 p=0.008). Using this cut-off, 30 out of 59 (50.8%) patients with a RBV concentration above 2.3 11 μg/mL developed anemia, while this occurred in only 27/108 (25.0%) patients with RBV 12 concentrations below 2.3 μg/mL (χ2=8.08, p=0.003). 13
Many factors previously linked to anemia were also included in multivariate logistic regression 14 analysis. As summarized in Table 2 , carrier of variant allele (OR=0.29, p=0.005) and RBV 15 plasma concentrations below 2.3 μg/mL (OR=0.42, p=0.016) were independently associated with 16 protection against clinically significant anemia. The probability of developing anemia based on 17 these two predictive factors is shown in Figure 2 . Considering patients with RBV concentrations 18 below 2.3 μg/mL, the predicted probability of developing anemia was 35.5% for patients with 19 wild type genotype for all SNPs (n=72) and 13.8% for patients with at least one SNP with a 20 variant allele (n=31). Considering patients with RBV concentrations above 2.3 μg/mL, the 21 predicted probability for patients with wild type genotype for all SNPs (n=47) was 56.8%, 22 compared with 27.5% for patients with at least one SNP with variant allele (n=17). 23 As shown in Figure 3 carriers of ITPA variants had a smaller decrease of Hb as compared to 1 patients with wild type ITPA genotype. In the same figure and analysis it is also apparent that, 2 regardless of the RBV concentration, in carriers of ITPA variants the magnitude of Hb 3 decrement was found to have no significant association with plasma RBV concentration (rho=-4 0.17, p=0.28), while the magnitude of Hb decrease among patients with the WT ITPA genotype 5 had a strong and significant association with RBV concentrations (rho=-0.20, p=0.035). 6
DISCUSSION. 1
Recently several genetic variants associated with substantial effects on both efficacy and toxicity 2 of PEG/IFN and ribavirin have been identified. SNPs in the IL28B gene were found to be 3 strongly associated with response to therapy of chronic genotype 1 HCV infection 23-27 , and 4 SNPs in the ITPA gene were identified as predictors of RBV treatment-associated anemia in the 5 European-American and Japanese populations 5, 14, 15, 28 . The anemia experienced as a 6 consequence of PEG/IFN and RBV combination therapy is primarily caused by a RBV-induced 7 haemolysis and secondarily by interferon-induced bone marrow toxicity. Ribavirin toxicity can 8 be explained by the accumulation of RBV phosphate metabolites in erythrocytes, oxidative 9 damage and consequent cell lysis 29 . The impact of anemia on the outcome of anti-HCV infection 10 therapy is substantial, since RBV dose-reduction or early treatment interruption due to anemia 11 often leads to suboptimal drug intake and a higher chance of treatment failure 30 . The possibility 12 of identifying those patients who are more likely to undergo significant Hb loss while on 13 treatment might be helpful in order to implement those measures which might limit the impact 14 of anemia on treatment outcome. 15
In this study the newly identified genetic polymorphisms of ITPA as well as RBV 16 pharmacokinetic exposure, using RBV trough plasma concentration, confirmed their value as 17 predictors of treatment-induced anemia, as established by HB reduction after 4 weeks of 18 PEG/IFN-RBV treatment. Furthermore, we observed that baseline Hb was correlated with Hb 19 reduction. However having a higher baseline HB concentration is a biologically benign 20 condition, which testifies to a higher functional reserve as compared to the other patients. For 21 pure numerical reasons such condition is more vulnerable to a HB loss, since HB loss is here 22 measured in terms of absolute values rather than percentage HB loss from baseline. 23
Although, in addition to ITPA polymorphisms and RBV concentration, a series of individual 1 features such as age, platelet count, haemoglobin concentration and haptoglobin phenotype were 2 found to have some degree of association with the risk of anemia 8, 31, 32 , the only modifiable 3 factor of these variables is RBV pharmacokinetic exposure, which shows remarkable variability 4 among HCV-infected patients 33 . Thus, the early assessment of RBV concentration is suggested 5 by some studies 34, 35 in order to adjust individual RBV dose. 6
Following the identification of ITPA polymorphism as the strongest predictor of anemia in 7 PEG/IFN-RBV recipients, the question arises as to how to integrate this newly identified genetic 8 marker with RBV trough concentration in order to predict and manage the individual risk of 9 anemia. According to our results, there is no apparent correlation between ITPA polymorphisms 10 and RBV pharmacokinetic exposure, as also expected by the reported lack of association 11 between ITPA polymorphism and treatment outcome. 12
Thus, the two variables analyzed here, ITPA functional polymorphism and RBV concentration, 13 retain their independent predictive values and display limited overlap in terms of predictive 14 value. As shown in figure 2, the reciprocal increase in predictive value provided by either 15 variable is significant. When relying upon RBV exposure, it is apparent that with high RBV 16 concentration the possession of ITPA variants is associated with a lower risk of anemia as 17 compared to patients with WT genotype and, changing the point of view, patients with the same 18 ITPA genetic profile have a higher risk of anemia in case of higher RBV concentration. 19
Thus, the introduction of the described ITPA genetic polymorphism substantially improves our 20 ability to predict the individual risk of treatment-induced anemia (perhaps also considering the 21 non-functional polymorphism rs6051702?). The main implication of our results is that the 22 possession of ITPA variants is associated with a rather limited median Hb loss, independent of 23 RBV concentration, even when RBV concentration is above the threshold of 2.3 µg/mL. In our 1 patients anemia occurred in 8 of 49 ITPA variant carriers (16.3%) and in 51 of 118 of ITPA WT 2 patients (43.2%). It is worth noting that the only 6 patients who had Hb value less than 10 g/dL 3 at week 4 were all ITPA WT carriers. 4
In practical terms, given that human genetic analysis is easier and quicker to perform, with 5 turnaround time shorter than TDM of RBV, and that the technique is far more widespread than 6 TDM, the baseline estimation of the individual risk of treatment-induced anemia seems now a 7 step closer to becoming common practice. In this perspective, RBV TDM might maintain a role 8 in the management of the prevailing proportion of patients with WT ITPA genotype, in whom 9 RBV concentration may be fruitfully modified by RBV dose adjustment. Since RBV 10 pharmacokinetic exposure is also associated with the rate of SVR 6, 11, 13, 27, 36, 37 , the same might 11 also apply to carriers of ITPA variants with suboptimal RBV concentration, in whom RBV dose 12 may be increased with a smaller risk of anemia. 13
In conclusion, this retrospective study confirms the high impact of ITPA SNPs on hemolytic 14 anemia and seems to suggest a cut-off value for trough plasma RBVconcentration. Although 15 more studies are needed to clarify and confirm the relationship between anemia, ITPA 16 polymorphism and RBV pharmacokinetics, these results show that estimating the risk of anemia 17 by relying upon both these two determinants was more accurate than the use of a single 18 assessment of either variable, assuming plasma RBV concentrations are a key factor to predict 19 anemia. Moreover, these data might form the basis for the development of an individual 20 screening algorithm able to reduce the impact of anemia on the rate of response to anti-HCV 21 treatment. 22 
